ArticleScientific reports2025
Temporal changes of hepatic drug-metabolizing enzymes mediated by hepatic ischemia-reperfusion injury and the protective effect of Oridonin.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ameliorative effects of aFrontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Hepatic ischemia-reperfusion injury (IRI) is a common complication associated with metabolic disturbances and postoperative liver failure. Despite its prevalence, there is still a significant gap in understanding the changes in hepatic drug-metabolizing enzymes-specifically cytochrome P450s (CYPs) and UDP-glucuronosyltransferases (UGTs)-that occur due to hepatic IRI and in identifying effective treatment strategies. This study highlights the temporal changes in the expression and activity of CYPs and UGTs mediated by hepatic ischemia-reperfusion injury, demonstrating a correlation between these enzymatic changes and indicators of liver injury. Our findings demonstrate that Oridonin (ORI), a natural monomer derived from the traditional Chinese medicinal herb Rabdosia rubescens, has notable anti-inflammatory and antioxidant properties. ORI was found to counteract the adverse effects of hepatic IRI on CYPs and UGTs, thus alleviating the metabolic disturbances associated with the injury. Moreover, ORI effectively inhibits inflammatory responses, oxidative stress, and apoptosis related to hepatic IRI. It does this by suppressing the NLRP3 inflammatory pathway, activating the Nrf2 endogenous antioxidant pathway, and modulating the levels of key proteins such as Bcl-2. ORI also demonstrated efficacy in reducing inflammation in a cell hypoxia/reoxygenation (H/R) model. These results suggest that ORI holds promise as a therapeutic candidate for the treatment of hepatic IRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.